Dr. Joseph Fakhoury provides an overview of the current treatment landscape for alopecia areata, reviewing approved Janus kinase (JAK) inhibitors for adolescents and adults, along with practical guidance on patient counseling and treatment expectations. He discusses factors associated with improved outcomes, including earlier intervention and lower disease severity at treatment initiation, while emphasizing that treatment responses may occur early, gradually, or later in the course of therapy. Dr. Fakhoury also provides an update on the expanding clinical pipeline, highlighting ongoing studies of additional JAK inhibitors and investigational non-JAK therapies that may further broaden the future of alopecia areata treatment.
